Sandoz Lowers Sales Growth Guidance, Raises Core Earnings Margin Forecast
Sandoz lowered its full-year sales growth guidance and raised its core earnings margin forecasts after short-term biosimilar supply constraints weighed on third-quarter results. It now expects net sales growth of 5–6% at constant exchange rates.
Swiss generic drugmaker Sandoz BX:D8Y on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on third-quarter results.The company now expects net sales to grow by 5-6% at constant exchange rates…